Translations:GLP-1 receptor agonist/20/en: Difference between revisions

From Azupedia
Jump to navigation Jump to search
VisualWikitext
FuzzyBot (talk | contribs)
14,895 edits
Importing a new version from external source
 
(No difference)

Latest revision as of 21:59, 5 February 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (GLP-1 receptor agonist)
==Approved==
*[[exenatide]] (brand names Byetta and Bydureon, manufactured by [[AstraZeneca]]), approved in 2005/2012
*[[liraglutide]] (Victoza for diabetes, Saxenda for obesity, manufactured by [[Novo Nordisk]]), approved in 2010
*[[albiglutide]] (Tanzeum, manufactured by [[GlaxoSmithKline|GSK]]), approved in 2014
*[[dulaglutide]] (Trulicity, manufactured by [[Eli Lilly and Company|Eli Lilly]]), approved in 2014
*[[lixisenatide]] (Lyxumia in Europe, Adlyxin in the United States, manufactured by [[Sanofi]]), approved in 2016
*[[semaglutide]] (Ozempic and Rybelsus for diabetes, Wegovy for obesity, manufactured by Novo Nordisk), approved in 2017
*[[tirzepatide]] (dual GLP-1 and [[Gastric inhibitory polypeptide receptor|GIP]] agonist; Mounjaro for diabetes, Zepbound for obesity, manufactured by Eli Lilly), approved in 2022

Approved

  • exenatide (brand names Byetta and Bydureon, manufactured by AstraZeneca), approved in 2005/2012
  • liraglutide (Victoza for diabetes, Saxenda for obesity, manufactured by Novo Nordisk), approved in 2010
  • albiglutide (Tanzeum, manufactured by GSK), approved in 2014
  • dulaglutide (Trulicity, manufactured by Eli Lilly), approved in 2014
  • lixisenatide (Lyxumia in Europe, Adlyxin in the United States, manufactured by Sanofi), approved in 2016
  • semaglutide (Ozempic and Rybelsus for diabetes, Wegovy for obesity, manufactured by Novo Nordisk), approved in 2017
  • tirzepatide (dual GLP-1 and GIP agonist; Mounjaro for diabetes, Zepbound for obesity, manufactured by Eli Lilly), approved in 2022
Retrieved from "https://wiki.tiffa.net/w/index.php?title=Translations:GLP-1_receptor_agonist/20/en&oldid=110970"